Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Fineline Cube Feb 9, 2026
Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Fineline Cube Feb 9, 2026
Company Medical Device

Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial

Fineline Cube Aug 29, 2023

Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...

Company Drug

Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...

Company Deals

Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine

Fineline Cube Aug 29, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...

Company Deals

BMS Partners with Cellares for Automated CAR-T Cell Therapy Production

Fineline Cube Aug 29, 2023

Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy...

Company Deals

Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification

Fineline Cube Aug 29, 2023

A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...

Company

Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales

Fineline Cube Aug 29, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...

Company Drug

Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment

Fineline Cube Aug 29, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...

Company Drug

Zhejiang Huahai Pharmaceutical Receives FDA Approval for Generic Vyvanse

Fineline Cube Aug 29, 2023

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced the receipt...

Company

Antengene’s Xpovio Price Reduced by 37% in China, Aiding Patient Access

Fineline Cube Aug 29, 2023

Antengene Corp., Ltd (HKG: 6996) has announced a significant price reduction for its drug Xpovio...

Policy / Regulatory

China’s 9th National VBP Tender Round Targets CNS Drugs and Includes Oncology Therapies

Fineline Cube Aug 29, 2023

The National Allied Procurement Office has released a notification initiating the information filing process for...

Policy / Regulatory

NMPA Revises Drug Conditional Approval Procedures: Streamlined Processes and Requirements

Fineline Cube Aug 29, 2023

The National Medical Products Administration (NMPA) has released the “Drug Conditional Approval Filing Review and...

Company Deals

GenFleet Therapeutics and Verastem Oncology Ink Licensing Deal for RAS Pathway Cancer Therapies

Fineline Cube Aug 29, 2023

China-based GenFleet Therapeutics has entered into an exclusive licensing and early development agreement with US...

Company Drug

Boehringer Ingelheim Submits Three INDs for Survodutide Phase III Trials in China

Fineline Cube Aug 29, 2023

Germany-based Boehringer Ingelheim (BI) has announced the submission of three Investigational New Drug (IND) filings...

Company

Harbour BioMed Reports First Profitable Half-Year in H1 2023 Financial Results

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half...

Company Medical Device

Allurion’s Non-Invasive Weight-Loss Balloon Debuts at Ruijin Hospital’s Hainan Subsidiary

Fineline Cube Aug 28, 2023

US-based Allurion’s (NYSE: ALUR) weight-loss intragastric balloon has been first applied in Shanghai Ruijin Hospital’s...

Company Drug

Janssen Submits Rybrevant for FDA Review as First-Line NSCLC Treatment

Fineline Cube Aug 28, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has submitted an additional indication for review...

Company Policy / Regulatory

AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare

Fineline Cube Aug 28, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US...

Company Drug

MSD Initiates Phase III Trial for PCSK9 Inhibitor MK-0616 in LDL Cholesterol Reduction

Fineline Cube Aug 28, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has commenced Phase III development for its experimental...

Company Deals

Henlius Biotech Expands Licensing Agreement with KGbio for PD-1 Inhibitor

Fineline Cube Aug 28, 2023

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced an update to the licensing agreement...

Company Drug

Sandoz Receives FDA Clearance for First Biosimilar to Biogen’s Tysabri

Fineline Cube Aug 28, 2023

The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has received regulatory clearance from the US...

Posts pagination

1 … 437 438 439 … 621

Recent updates

  • Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials
  • InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials
  • Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China
  • Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication
  • Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhongsheng Pharma Reports Positive Phase III Data for Onradivir Pediatric and Adolescent Influenza Trials

Company Drug

InnoCare Pharma’s ICP-538 Becomes First VAV1 Molecular Glue Degrader to Enter China Clinical Trials

Company Drug

Betta Pharma Secures NMPA Approval for Beizeting, First Domestic Pertuzumab Biosimilar in China

Company Drug

Kelun-Biotech’s Jiatailai Secures Fourth NMPA Approval for HR+/HER2- Breast Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.